Farmers & Merchants Investments Inc. Decreases Position in Eli Lilly and Company $LLY

Key Points

• Farmers & Merchants Investments Inc. reduced its stake in Eli Lilly and Company by 2.4%, leaving them with 46,109 shares, valued at approximately $35.94 million.
• Insider transactions saw Director J Erik Fyrwald purchase 1,565 shares at an average price of $642.33 per share, while EVP Daniel Skovronsky bought 1,000 shares at $634.40 per share.
• Eli Lilly reported earnings of $6.31 per share for the most recent quarter, surpassing analysts' expectations of $5.59, with revenue hitting $15.56 billion.

Farmers & Merchants Investments Inc. trimmed its holdings in Eli Lilly and Company (NYSE:LLY - Free Report) by 2.4% during the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 46,109 shares of the company's stock after selling 1,114 shares during the period. Eli Lilly and Company comprises about 1.0% of Farmers & Merchants Investments Inc.'s investment portfolio, making the stock its 17th biggest position. Farmers & Merchants Investments Inc.'s holdings in Eli Lilly and Company were worth $35,943,000 at the end of the most recent quarter.

Several other large investors have also made changes to their positions in the business. Main Line Retirement Advisors LLC lifted its position in shares of Eli Lilly and Company by 2.5% in the second quarter. Main Line Retirement Advisors LLC now owns 849 shares of the company's stock valued at $662,000 after acquiring an additional 21 shares in the last quarter. Rooted Wealth Advisors Inc. lifted its position in shares of Eli Lilly and Company by 6.8% in the second quarter. Rooted Wealth Advisors Inc. now owns 568 shares of the company's stock valued at $451,000 after acquiring an additional 36 shares in the last quarter. Lewis Asset Management LLC lifted its position in shares of Eli Lilly and Company by 131.1% in the second quarter. Lewis Asset Management LLC now owns 2,299 shares of the company's stock valued at $1,792,000 after acquiring an additional 1,304 shares in the last quarter. Capstone Wealth Management LLC lifted its position in shares of Eli Lilly and Company by 53.0% in the second quarter. Capstone Wealth Management LLC now owns 491 shares of the company's stock valued at $383,000 after acquiring an additional 170 shares in the last quarter. Finally, Park Avenue Securities LLC lifted its position in shares of Eli Lilly and Company by 1.0% in the second quarter. Park Avenue Securities LLC now owns 23,900 shares of the company's stock valued at $18,631,000 after acquiring an additional 239 shares in the last quarter. 82.53% of the stock is currently owned by hedge funds and other institutional investors.

Eli Lilly and Company Trading Up 0.4%

Shares of NYSE LLY traded up $3.33 during trading hours on Monday, reaching $755.32. The stock had a trading volume of 2,524,436 shares, compared to its average volume of 3,388,311. The company has a current ratio of 1.28, a quick ratio of 1.00 and a debt-to-equity ratio of 1.86. The firm has a market cap of $714.88 billion, a price-to-earnings ratio of 49.37, a P/E/G ratio of 1.05 and a beta of 0.47. The business's fifty day moving average price is $737.49 and its two-hundred day moving average price is $769.01. Eli Lilly and Company has a 52-week low of $623.78 and a 52-week high of $939.30.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last posted its earnings results on Thursday, August 7th. The company reported $6.31 earnings per share for the quarter, topping analysts' consensus estimates of $5.59 by $0.72. The company had revenue of $15.56 billion during the quarter, compared to analyst estimates of $14.40 billion. Eli Lilly and Company had a return on equity of 92.72% and a net margin of 25.91%.Eli Lilly and Company's revenue was up 37.6% on a year-over-year basis. During the same quarter in the prior year, the business earned $3.92 earnings per share. Eli Lilly and Company has set its FY 2025 guidance at 21.750-23.000 EPS. Analysts expect that Eli Lilly and Company will post 23.48 EPS for the current fiscal year.

Wall Street Analyst Weigh In

LLY has been the topic of several research analyst reports. Leerink Partners restated a "market perform" rating and issued a $715.00 price objective on shares of Eli Lilly and Company in a research report on Thursday, August 7th. DZ Bank raised Eli Lilly and Company from a "hold" rating to a "strong-buy" rating in a report on Thursday, August 14th. Hsbc Global Res raised Eli Lilly and Company from a "moderate sell" rating to a "hold" rating in a report on Wednesday, August 27th. Daiwa America cut Eli Lilly and Company from a "strong-buy" rating to a "hold" rating in a report on Sunday, August 17th. Finally, JPMorgan Chase & Co. reduced their target price on Eli Lilly and Company from $1,100.00 to $1,050.00 and set an "overweight" rating on the stock in a report on Tuesday, September 16th. One equities research analyst has rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating and nine have assigned a Hold rating to the company's stock. According to data from MarketBeat, Eli Lilly and Company has an average rating of "Moderate Buy" and a consensus price target of $939.61.

Insider Transactions at Eli Lilly and Company

In related news, Director J Erik Fyrwald purchased 1,565 shares of the business's stock in a transaction on Tuesday, August 12th. The shares were bought at an average cost of $642.33 per share, with a total value of $1,005,246.45. Following the transaction, the director owned 74,578 shares of the company's stock, valued at approximately $47,903,686.74. This trade represents a 2.14% increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Jamere Jackson purchased 200 shares of the business's stock in a transaction on Friday, August 8th. The shares were bought at an average cost of $639.56 per share, for a total transaction of $127,912.00. Following the completion of the transaction, the director directly owned 9,402 shares in the company, valued at $6,013,143.12. This trade represents a 2.17% increase in their position. The disclosure for this purchase can be found here. Insiders acquired 4,514 shares of company stock worth $2,894,841 over the last 90 days. Insiders own 0.14% of the company's stock.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.